University of Missouri School of Medicine MU Health School of Medicine
News Divider
            


World Ophthalmology Congress Brings MU Discoveries Into Focus


Nanomedicine research could help millions suffering from corneal conditions

Mohan
Rajiv Mohan, PhD
A University of Missouri research program that examines how nanotechnology could treat corneal diseases will be featured at the 2010 World Ophthalmology Congress from June 5 to June 9, 2010. Rajiv Mohan, PhD, associate professor of ophthalmology at the MU School of Medicine, will present how nanoparticles could be paired with therapeutic genes to deliver new treatments to corneal tissue. The promising new therapy could help millions who suffer from corneal scarring, wounds and other conditions.

Mohan was one of only five basic scientists invited to make a presentation at the nanotechnology session of the meeting, which will draw more than 6,000 attendees to Berlin.

"Because the meeting is primarily for physicians to discuss clinical care, basic science research that is presented must be able to translate from the bench to the bedside," Mohan said. "This selection is a direct reflection of MU's commitment to translational research in ophthalmology and to discoveries campuswide."

The cornea is the dome-shaped surface that functions as the eye's outermost layer. It is the first line of defense in shielding the eye from injury as well as infections. Corneal haze, scarring and abnormal blood vessel development are among the leading causes of vision impairment in the world and affect approximately 1.5 million Americans every year. Abnormal wound healing due to corneal injury or infection has been shown to play a critical role in causing these and other corneal disorders and diseases.

Mohan's laboratory is researching how hybrid gold nanoparticles and biodegradable polymeric nanoparticles can be used as a nonviral carrier to deliver gene therapy to the cornea. The nanoparticle-based gene therapy has shown minimal side effects in preclinical studies.

"The current nonviral vectors, or gene delivery vehicles, are incapable of delivering therapeutic levels of genes into the cells of the cornea," Mohan said. "Nanoparticles, because they are smaller, could provide a less invasive option for delivering the gene therapy effectively while reducing the risk of infection and side effects from treatment."

Mohan's corneal gene therapy research is funded by more than $2.8 million in grants from the National Eye Institute and Department of Veterans Affairs. The Association for Research in Vision and Ophthalmology recently identified findings from his laboratory as among the "the newest and most innovative" in the field of nanotechnology for drug and gene delivery.

The World Ophthalmology Congress brings together ophthalmologists to enhance education and improve access to the highest quality eye care. More information about its efforts to preserve and restore vision is available at http://www.icoph.org/advancing_leadership/ico_commitments_programs.html


MU Health Magazine

Divider

News and Events

Evans Evans Named Associate Dean and Chief Academic Officer for Springfield Clinical Campus
Role is to engage Columbia and Springfield leaders to provide strategic direction and vision
Robin Kruse, PhD Lack of Research Keeps End-of-Life Care in Status Quo
MU researcher finds only 10 clinical trials conducted in hospices since 1985, says more studies could improve patient care

Govindarajan MU Neurologist Earns National Education Honor
Raghav Govindarajan, MD, to receive National Golden Apple Award for Teaching Excellence

David Beversdorf Blood Pressure Medicine May Improve Conversational Skills of Individuals with Autism
Propranolol found to boost performance on six key components of communication

HMI Health Management and Informatics Professor Leads Largest Health Survey in Missouri
MU research center receives $2.13 million grant to survey more than 52,000 Missourians
Kattesh Katti, PhD MU Radiology Professor Named India’s Person of the Year in Science
Katti honored for breakthrough research in nanomedicine and green nanotechnology
Frederick Fraunfelder, MD Chickenpox, Shingles Vaccine May Cause Corneal Inflammation in Some Patients
Primary care physicians should be aware of possible vision side effect for susceptible patients
Infant-friendly Flu Vaccine Infant-friendly Flu Vaccine Developed with Key Protein
Natural additive offers protection against flu for babies younger than six months
Rural Area Medical School Program Addresses Rural Physician Shortage
Service learning enhances medical training, may increase rural practitioners




Media Relations
University of Missouri Health System
One Hospital Drive, DC028.00
Columbia, MO 65212
24/7 on-call pager: (573) 876-0708

Mary Jenkins
jenkinsmg@health.missouri.edu
(573) 882-7299

Jeff Hoelscher
hoelscherj@health.missouri.edu
(573) 884-1608

Derek Thompson
thompsonder@health.missouri.edu
(573) 882-3323

Diamond Dixon
DixonDi@health.missouri.edu
(573) 884-7541

Justin Kelley (Photographer)
kelleyju@health.missouri.edu
(573) 882-5786
Pager (573) 397-9289


Web Communications
University of Missouri Health System
One Hospital Drive, MA204G, DC018.00
Columbia, MO 65212
(573) 884-0298

Jennifer Orford
orfordj@health.missouri.edu
(573) 882-0298

Jesslyn Chew
chewj@missouri.edu
(573) 884-2891

Velvet Hasner
hasnerv@health.missouri.edu
(573) 884-1115

Justin Willett
willettj@health.missouri.edu
(573) 884-7740



Printer Friendly
Follow us on Twitter!   Facebook   YouTube Videos   Instagram   Pinterest  
Website created and maintained by the Office of Communications. Contact the MU School of Medicine.
Revised: April 27, 2013 - Copyright © 2014 - Curators of the University of Missouri. All rights reserved. DMCA and other copyright information. An equal opportunity/access/affirmative action/pro-disabled and veteran employer.